Smets Lien, Debucquoy Annelies, Oldenburger Eva, Van Audenhove Chantal, Debrun Lynn, Dekervel Jeroen, Bislenghi Gabriele, D'Hoore André, Wolthuis Albert, Haustermans Karin
Department of Radiation Oncology, Universitair Ziekenhuis Leuven, 3000 Leuven, Belgium.
LUCAS KU Leuven Center for Care Research & Consultancy, 3000 Leuven, Belgium.
Cancers (Basel). 2023 Jan 28;15(3):806. doi: 10.3390/cancers15030806.
Surgery is the primary component of curative treatment for patients with rectal cancer. However, patients with a clinical complete response (cCR) after neo-adjuvant treatment may avoid the morbidity and mortality of radical surgery. An organ-sparing strategy could be an oncological equivalent alternative. Therefore, shared decision making between the patient and the healthcare professional (HCP) should take place. This can be facilitated by a patient decision aid (PtDA). In this study, we developed a PtDA based on a literature review and the key elements of the Ottawa Decision Support Framework. Additionally, a qualitative study was performed to review and evaluate the PtDA by both HCPs and former rectal cancer patients by a Delphi procedure and semi-structured interviews, respectively. A strong consensus was reached after the first round (I-CVI 0.85-1). Eleven patients were interviewed and most of them indicated that using a PtDA in clinical practice would be of added value in the decision making. Patients indicated that their decisional needs are centered on the impact of side effects on their quality of life and the outcome of the different options. The PtDA was modified taking into account the remarks of patients and HCPs and a second Delphi round was held. The second round again showed a strong consensus (I-CVI 0.87-1).
手术是直肠癌患者根治性治疗的主要组成部分。然而,新辅助治疗后达到临床完全缓解(cCR)的患者可避免根治性手术带来的发病风险和死亡风险。保留器官策略可能是一种等效的肿瘤学替代方案。因此,患者与医疗保健专业人员(HCP)之间应进行共同决策。患者决策辅助工具(PtDA)有助于实现这一点。在本研究中,我们基于文献综述和渥太华决策支持框架的关键要素开发了一种PtDA。此外,还进行了一项定性研究,分别通过德尔菲法和半结构化访谈,让HCP和直肠癌患者对该PtDA进行审查和评估。第一轮后达成了强烈共识(I-CVI 0.85-1)。对11名患者进行了访谈,他们中的大多数人表示,在临床实践中使用PtDA对决策具有附加价值。患者表示,他们的决策需求集中在副作用对其生活质量的影响以及不同选择的结果上。根据患者和HCP的意见对PtDA进行了修改,并进行了第二轮德尔菲法。第二轮再次显示出强烈共识(I-CVI 0.87-1)。